Company / R&D Expense
X4 Pharmaceuticals, Inc R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$72.0M
FY2025
5-year range
$20.3M / $72.0M
FY2021-FY2025
Trend
+17.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 5 consecutive years, from $18M in FY2018 to $72M in FY2025.
Based on SEC 10-K filings.
$72M in FY2025 with a 5-year CAGR of +28.8%.
Improved from $42M to $72M over the past 3 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +19.8%
- 5-Year CAGR
- +28.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- X4 Pharmaceuticals, Inc's r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +28.8%, indicating consistent growth.
- In FY2025, r&d expense increased 17.9% year-over-year.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $72.0M | +17.9% |
| FY2024 | $61.1M | +45.6% |
| FY2022 | $41.9M | +39.0% |
| FY2021 | $30.2M | +48.3% |
| FY2020 | $20.3M | +14.1% |
| FY2018 | $17.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026